Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
2.
J Endocrinol Invest ; 42(11): 1361-1363, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31006073

ABSTRACT

INTRODUCTION: A new class of drugs in the treatment of cystic fibrosis (CF) includes two agents: lumacaftor, which corrects CFTR channel protein, and ivacaftor, which increases CFTR channel activity. In our previous study we recruited 50 stable adults with CF and 16 of them showed growth hormone deficit (GHD): 7 patients severe and 9 patients partial GHD. MATERIAL AND METHODS: We decided to re-evaluate ten patients with the GHRH + arginine test of whom only five were treated with lumacaftor/ivacaftor. RESULTS: All CF patients in therapy with lumacaftor/ivacaftor showed a marked improvement in GHD. Two patients moved from a severe GHD to a normal response to the GH/IGF-1 axis test, and three patients who had partial GHD moved to normal response. CONCLUSION: The pituitary gland may be damaged by CF disease and could benefit of the action of correcting drugs.


Subject(s)
Aminophenols/therapeutic use , Aminopyridines/therapeutic use , Benzodioxoles/therapeutic use , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/drug therapy , Growth Disorders/prevention & control , Human Growth Hormone/metabolism , Insulin-Like Growth Factor I/metabolism , Mutation , Quinolones/therapeutic use , Adult , Cystic Fibrosis/genetics , Cystic Fibrosis/pathology , Drug Combinations , Female , Follow-Up Studies , Growth Disorders/pathology , Humans , Male , Middle Aged , Prognosis
3.
Transplant Proc ; 50(10): 3732-3738, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30577264

ABSTRACT

OBJECTIVES: Lung transplantation is currently the only treatment for end-stage respiratory failure in patients with cystic fibrosis (CF). In this study we retrospectively analyzed our experience since the start of the transplantation program in 1996 with focus on survival analysis. METHODS: All patients with CF who underwent lung transplant at our center were included (1996-2016). Survival analysis after lung transplant was performed using the Kaplan-Meier estimate, comparing by sex and by 4 eras (1996-2000, 2001-2005, 2006-2010, and 2011-2016). RESULTS: In a 20-year period, 243 patients with CF were listed for lung transplant; 123 patients (61 male, 62 female) underwent transplant, and 85 died while waiting for donor organs. The mean (SD) and median age at transplant was 27.7 (8.7) years and 26.9 years (range, 9.1 - 52.1 years), respectively. Mean (SD) forced expiratory volume in the first second was 27.6 (9.7)% predicted; 115 patients (92.0%) were pancreatic insufficient, and 43 patients (34.0%) had CF-related diabetes. Removing patients with CF who died within the first 3 postoperative months, the mean (SD) and median survival after transplant were 8.2 (5.7) years and 7.5 years (range, 3 months-20 years), respectively. Overall post-lung transplant 1-year survival was 93.6%, 5-year survival was 71.4%, 10-year survival was 53.6%, 15-year survival was 36.7%, and 20-year survival was 31.6%. We found no difference in survival between sex (P = .22) and among the 4 eras (P = .56). CONCLUSIONS: Survival after lung transplant in our single center is similar to international data.


Subject(s)
Cystic Fibrosis/mortality , Cystic Fibrosis/surgery , Lung Transplantation/mortality , Adolescent , Adult , Child , Female , Follow-Up Studies , Humans , Italy , Kaplan-Meier Estimate , Lung Transplantation/methods , Male , Middle Aged , Retrospective Studies , Young Adult
4.
Respir Med ; 145: 200-205, 2018 12.
Article in English | MEDLINE | ID: mdl-30509709

ABSTRACT

BACKGROUND: Pregnancy in CF women is no longer an exceptional event, but few information on its effect on clinical status in European CF patients are available. This study describes Italian CF pregnant population, to investigate its effect on CF woman. METHODS: Data were collected (2010-2015) by the Italian CF Registry. A case-control study was performed between pregnant and never pregnant women. RESULTS: A total of 81 pregnant women (aged 18-45ys) were identified with a mean age at pregnancy of 31ys. Median age at diagnosis resulted higher in cases (P = 0.010). A decline from 6 to 12 months before pregnancy to one year after delivery in BMI (P = 0.034), in FEV1 (P < 0.001) and FVC (P < 0.001) was registered among cases. Difference in change between cases and controls was found for the BMI (P = 0.006); weak evidence of difference in FEV1 (p = 0.080) and FVC (p = 0.056) were noted between the groups. CONCLUSION: Data from ICFR show that CF women can become mother with only slight adverse effect on their nutritional status. Further study should be carried out to investigate long term effect of pregnancy on lung function.


Subject(s)
Cystic Fibrosis/physiopathology , Forced Expiratory Volume , Nutritional Status , Pregnancy Complications/physiopathology , Adolescent , Adult , Body Mass Index , Female , Humans , Italy , Middle Aged , Pregnancy , Registries , Young Adult
5.
J Endocrinol Invest ; 41(5): 591-596, 2018 May.
Article in English | MEDLINE | ID: mdl-29098662

ABSTRACT

PURPOSE: Patients with cystic fibrosis (CF) present with signs and symptoms that overlap with those of adult growth hormone deficiency (GHD) syndrome: loss of muscle mass, bone fragility and lower stress tolerance. In literature, the prevalence of GHD in pediatric CF patients is higher than general population, but these studies have been performed on children with growth delay. To our knowledge, there are no studies on adult patients. The aim of this paper is to evaluate GH-IGF1 axis in an adult CF population. METHODS: Fifty clinically stable adult patients, 30 males; age 36 ± 2 years; BMI 21.39 ± 0.22 kg/m2 and FEV1 67 ± 4% were studied. Data regarding glycometabolic status and results of pituitary, thyroid, parathyroid, gonadal and adrenal function tests were recorded. All patients underwent a GH releasing hormone (GHRH) + Arginine stimulation test to confirm a GHD. RESULTS: GHRH + Arginine test revealed the presence of GHD in 16 patients (32%); specifically 7 patients had a severe deficiency and 9 a partial deficiency. CONCLUSIONS: Adult patients with CF may show GHD. These patients should be followed over time to assess if the GHD could impact the clinical progression of CF.


Subject(s)
Biomarkers/analysis , Cystic Fibrosis/complications , Growth Disorders/diagnosis , Human Growth Hormone/deficiency , Insulin-Like Growth Factor I/metabolism , Adolescent , Adult , Arginine/metabolism , Female , Follow-Up Studies , Growth Disorders/etiology , Growth Disorders/metabolism , Humans , Male , Middle Aged , Prognosis , Young Adult
6.
J Cyst Fibros ; 14(2): 203-10, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25458463

ABSTRACT

BACKGROUND: In cystic fibrosis (CF) the defective CF transmembrane conductance regulator protein may be responsible for the impaired transport of glutathione (GSH), the first line defense of the lung against oxidative stress. The aim of this single-blind, randomized, placebo-controlled trial was to evaluate the effect of inhaled GSH in patients with CF. METHODS: 54 adult and 51 pediatric patients were randomized to receive inhaled GSH or placebo twice daily for 12 months. RESULTS: Twelve month treatment with inhaled GSH did not achieve our predetermined primary outcome measure of 15% improvement in FEV1%. Only in patients with moderate lung disease, 3, 6 and 9 months therapy with GSH resulted in a statistically significant increase of FEV1 values from the baseline. Moreover GSH therapy improved 6-minute walking test in pediatric population. GSH was well tolerated by all patients. CONCLUSIONS: Inhaled GSH has slight positive effects in CF patients with moderate lung disease warranting further study. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01450267; URL: www.clinicaltrialsgov.


Subject(s)
Biological Transport/drug effects , Cystic Fibrosis , Glutathione , Lung , Administration, Inhalation , Adolescent , Adult , Antioxidants/administration & dosage , Antioxidants/pharmacokinetics , Child , Cystic Fibrosis/drug therapy , Cystic Fibrosis/metabolism , Drug Monitoring/methods , Exercise Test/drug effects , Female , Forced Expiratory Volume/drug effects , Glutathione/administration & dosage , Glutathione/pharmacokinetics , Humans , Lung/drug effects , Lung/metabolism , Male , Oxidative Stress/drug effects , Severity of Illness Index , Single-Blind Method , Treatment Outcome
7.
Transplant Proc ; 46(1): 295-7, 2014.
Article in English | MEDLINE | ID: mdl-24507071

ABSTRACT

Infection with Burkholderia species is typically considered a contraindication leading to transplantation in cystic fibrosis (CF). However, the risks posed by different Burkholderia species on transplantation outcomes are poorly defined. We present the case of a patient with CF who underwent lung transplantation due to a severe respiratory failure from chronic airways infection with Burkholderia pyrrocinia (B. cepacia genomovar IX) and pan-resistant Pseudomonas aeruginosa. The postoperative course was complicated by recurrent B. pyrrocinia infections, ultimately lea ding to uncontrollable sepsis and death. This is the first case report in CF of Burkholderia pyrrocinia infection and lung transplantation, providing further evidence of the high risk nature of the Burkholderia species.


Subject(s)
Burkholderia Infections/metabolism , Burkholderia , Cystic Fibrosis/microbiology , Cystic Fibrosis/surgery , Lung Transplantation , Adolescent , Burkholderia Infections/diagnostic imaging , C-Reactive Protein/metabolism , Cystic Fibrosis/diagnostic imaging , Female , Humans , Postoperative Period , Risk , Tomography, X-Ray Computed , Treatment Outcome
8.
Minerva Pediatr ; 65(4): 389-98, 2013 Aug.
Article in English | MEDLINE | ID: mdl-24051972

ABSTRACT

AIM: Cystic fibrosis (CF) patients present an altered fatty acid (FA) metabolism characterized by imbalance in the arachidonic/docosohexasenoic acid (AA/DHA) ratio in favour of the former which can contribute to the increase in pulmonary inflammation. The present study aims to assess respiratory, nutritional, clinical and laboratory parameters, and inflammatory markers after six months of DHA supplementation in paediatric patients suffering from CF. METHODS: A dose of 1 g/10 kg/die was administered to ten CF patients of paediatric age for the first month and 250 mg/10 kg/die for the remaining 5 months. We carried out follow-ups at T0 (baseline), T6 (after six months of the diet) and T12 (six months after supplementation was interrupted) during which respiratory, nutritional, clinical and laboratory parameters were assessed. RESULTS: After six months of DHA supplementation inflammatory marker levels had diminished: interleukin 8 (IL-8) and Tumour Necrosis Factor Alfa (TNF-α) in serum, and calprotectin in stools. In addition, auxometric parameters were improved as was the clinical condition of patients, who tolerated DHA well. CONCLUSION: Dietetic integration with DHA seems to improve clinical condition and the inflammatory pulmonary and intestinal state of pediatric patients suffering from CF.


Subject(s)
Cystic Fibrosis/diet therapy , Dietary Supplements , Docosahexaenoic Acids/administration & dosage , Administration, Oral , Child , Female , Humans , Male
9.
J Cardiovasc Surg (Torino) ; 53(6): 817-20, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23207567

ABSTRACT

AIM: Pulmonary hypertension (PH) is frequently found in patients with advanced parenchymal lung diseases. In advanced stages, cystic fibrosis (CF) patients can develop PH and eventually cor pulmonale. Little is known about the prevalence of PH in CF patients and its impact on outcome. METHODS: We retrospectively studied a large cohort of CF patients evaluated for lung transplantation between 1995 and 2010. All the patients underwent right heart catheterization as part of the evaluation. We included 179 unique consecutive adult CF patients. Age was 24±9 years and 45.8% were women. RESULTS: Eighty-seven patients were transplanted (48.6%) and 65 died (36.3%) while waiting for LT. By right heart catheterization, 38.5% of the patients had PH (mean ≥25 mm Hg). PaCO(2) (P=0.045) and forced vital capacity (P=0.023) were independent predictors of PH in CF patients. The median survival (free of lung transplantation) was 13.4 months. After adjusting for several covariates, the presence of PH significantly increased mortality (hazard ratio, HR) (P<0.001). Pulmonary vascular resistance was associated with mortality (P=0.03). When both PH and PVR were included in the model, only PH predicted mortality. CONCLUSION: Pulmonary hypertension of mild degree is frequently found in CF patients with advanced lung disease and its presence significantly worsens survival.


Subject(s)
Cystic Fibrosis/mortality , Cystic Fibrosis/surgery , Hypertension, Pulmonary/epidemiology , Lung Transplantation , Waiting Lists , Adult , Cystic Fibrosis/complications , Female , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Male , Prevalence , Retrospective Studies , Risk Factors , Sensitivity and Specificity , Survival Rate , Young Adult
10.
Article in English | MEDLINE | ID: mdl-22669100

ABSTRACT

AIM:Pulmonary hypertension (PH) is frequently found in patients with advanced parenchymal lung diseases. In advanced stages, cystic fibrosis (CF) patients can develop PH and eventually cor pulmonale. Little is known about the prevalence of PH in CF patients and its impact on outcome. METHODS: We retrospectively studied a large cohort of CF patients evaluated for lung transplantation between 1995 and 2010. All the patients underwent right heart catheterization as part of the evaluation. We included 179 unique consecutive adult CF patients. Age was 24±9 years and 45.8% were women. RESULTS:Eighty-seven patients were transplanted (48.6%) and 65 died (36.3%) while waiting for LT. By right heart catheterization, 38.5% of the patients had PH (mean ≥25 mm Hg). PaCO2 (P=0.045) and forced vital capacity (P=0.023) were independent predictors of PH in CF patients. The median survival (free of lung transplantation) was 13.4 months. After adjusting for several covariates, the presence of PH significantly increased mortality (hazard ratio, HR) (P<0.001). Pulmonary vascular resistance was associated with mortality (P=0.03). When both PH and PVR were included in the model, only PH predicted mortality. CONCLUSION: Pulmonary hypertension of mild degree is frequently found in CF patients with advanced lung disease and its presence significantly worsens survival.

11.
Transpl Infect Dis ; 14(2): 188-91, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22093620

ABSTRACT

A 37-year-old patient with cystic fibrosis underwent double lung transplantation. She developed disseminated Scedosporium apiospermum infection 2 months after surgery. Along with multiple brain abscesses, lung infection, and chorioretinitis, a cardiac echo revealed 2 large intra-atrial mycetomas floating close to the right upper pulmonary vein orifice. The mycetomas were removed through a trans-atrial approach under cardiopulmonary by pass; histology and cultures confirmed the diagnosis. Despite intensive treatment, the patient succumbed from massive brain hemorrhage on the 10th postoperative day.


Subject(s)
Cystic Fibrosis/therapy , Heart Atria/pathology , Lung Transplantation/adverse effects , Mycetoma/microbiology , Scedosporium/isolation & purification , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Fatal Outcome , Female , Humans , Mycetoma/pathology
12.
Transplant Proc ; 43(4): 1162-3, 2011 May.
Article in English | MEDLINE | ID: mdl-21620078

ABSTRACT

During their life, cystic fibrosis (CF) patients may require thoracic surgical procedures for a number of reasons before undergoing lung transplantation. In the past, this has been considered to be a contraindication to lung transplantation. However, a meticulous surgical technique and careful intraoperative management allows one to perform the transplantation safely. Herein we have reported our experience with CF patients undergoing lung transplantation after previous surgical treatment for pneumothorax or bronchiectasis.


Subject(s)
Bronchiectasis/surgery , Cystic Fibrosis/surgery , Lung Transplantation , Pneumothorax/surgery , Thoracic Surgical Procedures , Adolescent , Adult , Bronchiectasis/etiology , Cystic Fibrosis/complications , Female , Humans , Italy , Lung Transplantation/adverse effects , Male , Patient Selection , Pneumothorax/etiology , Recurrence , Risk Assessment , Risk Factors , Thoracic Surgical Procedures/adverse effects , Tissue Adhesions , Treatment Outcome , Young Adult
13.
Clin Transplant ; 25(1): E46-51, 2011.
Article in English | MEDLINE | ID: mdl-20642799

ABSTRACT

C. difficile (C. d.) is the main cause of antibiotic-associated diarrhea and colitis. It is shown in literature a high asymptomatic carriage rate of C. d. in patients with cystic fibrosis (CF), though C. d.-related colitis is an uncommon complication in these patients, despite the use of multiple high-dose antibiotic regimes and the frequency of hospital admissions. Lung transplantation with the associated immunosuppression and aggressive antibiotic therapy may increase the risk of the clinical manifestation of C. d. In this paper, we describe three cases of severe C. d. colitis in patients with CF following lung transplantation and illustrate our experience in the diagnosis and management of these patients.


Subject(s)
Clostridioides difficile/pathogenicity , Colitis/etiology , Cystic Fibrosis/complications , Diarrhea/etiology , Enterocolitis, Pseudomembranous/microbiology , Lung Transplantation , Postoperative Complications , Adult , Anti-Bacterial Agents/therapeutic use , Colitis/drug therapy , Cystic Fibrosis/therapy , Diarrhea/drug therapy , Enterocolitis, Pseudomembranous/diagnosis , Enterocolitis, Pseudomembranous/drug therapy , Female , Humans , Male , Survival Rate , Treatment Outcome
14.
Transplant Proc ; 42(4): 1279-80, 2010 May.
Article in English | MEDLINE | ID: mdl-20534280

ABSTRACT

Airway complications (AC) are considered a serious cause of morbidity after lung transplantation (LT). Mechanical dilatation, laser vaporization, and silicone stent placement usually solve it. However, the use of self-expandable metallic stents (SENS) may be indicated in selected cases. Ten lung transplant recipients with AC were treated with SENS. Six patients underwent LT for cystic fibrosis, 2 for idiopathic pulmonary fibrosis, 1 for bronchiectasis, and 1 for emphysema. All patients received at least 1 treatment attempt with dilatation and silicone stent placement. The indications for SENS placement were the presence of a tortuous airway axis with stenosis and malacia of the right main bronchus in 5 patients; a long stenosis of the main and intermediate right bronchus involving the upper lobe orifice in 3 patients; or malacia that could not be stabilized with silicone stents in 3 cases. In 1 patient the procedure was bilateral. Functional improvement was immediate with a mean forced expiratory volume at 1 second (FEV(1)) gain of 35%. No stent dislocation was observed. Symptoms did not occur again in 5 patients with previous recurrent episodes of pneumonia. One stenosis, which was due to the ingrowth of granulation tissue occurred at 6 months after the procedure, was successfully treated with mechanical dilatation and laser vaporization. The deployment of SENS in a selected group of patients with AC after LT was easy, safe, and effective.


Subject(s)
Lung Transplantation/adverse effects , Stents , Alloys , Cystic Fibrosis/etiology , Cystic Fibrosis/surgery , Cystic Fibrosis/therapy , Dilatation/methods , Emphysema/etiology , Emphysema/surgery , Emphysema/therapy , Forced Expiratory Volume , Humans , Pulmonary Fibrosis/etiology , Pulmonary Fibrosis/surgery , Pulmonary Fibrosis/therapy , Silicones , Treatment Outcome
15.
Transplant Proc ; 40(6): 2003-5, 2008.
Article in English | MEDLINE | ID: mdl-18675114

ABSTRACT

Lung transplantation (LT) is the only effective form of therapy for cystic fibrosis (CF) associated with end-stage pulmonary failure. In Italy, the management of CF is regulated by national law, which has instituted regional centers for care and follow-up of all CF patients. LT has been performed since 1992 in only nine LT certified centers. The structured national organization has led to a unified database for LT for CF. As of December 2006, 197 bilateral LT (96 male and 94 female patients; 7 retransplants) have been performed. Of these, four had also liver or heart and liver transplantation, and three are long-term survivors. Overall median survival is 7 years. Mean age at transplantation is 26.5 years, and the mortality on the waiting list is 33.6%. Patients listed for transplant either received a suitable donor within a mean of 10 months or died within a mean of 5.5 months. The most frequent cause of death is bronchiolitis obliterans syndrome (BOS). Our nationwide database indicates the excellent results obtained by LT in FC. Still, mortality on the waiting list remains a challenge and long-term outcome is limited by BOS.


Subject(s)
Cystic Fibrosis/surgery , Lung Transplantation/statistics & numerical data , Bronchiolitis Obliterans/epidemiology , Cystic Fibrosis/complications , Female , Humans , Italy , Male , Postoperative Complications/classification , Postoperative Complications/epidemiology , Reoperation/statistics & numerical data , Respiratory Insufficiency/etiology , Respiratory Insufficiency/surgery , Retrospective Studies , Treatment Outcome
16.
Transplant Proc ; 40(6): 2001-2, 2008.
Article in English | MEDLINE | ID: mdl-18675113

ABSTRACT

Lung transplantation represents the only therapeutic option for patients affected by end-stage cystic fibrosis (CF). We performed 76 lung transplantations in 73 patients from 1996-2007. The mean time on the waiting list was 10+/-6 months. The median follow-up after the transplantation was 69.3 months. Twenty-one transplants (27.6%) were performed under cardiopulmonary bypass. Perioperative mortality, excluding retransplants, was 16.4% (12 patients) and the causes of death were sepsis, primary graft failure, and myocardial infarction. The overall survival was 74.5%+/-5%, 62.9%+/-5%, 54.1%+/-6%, and 43.4%+/-6% at 1, 3, 5, and 10 years, respectively. The accurate selection of potential recipients and the correct timing of referral and transplantation are factors that play crucial roles to obtain satisfactory results in term of improvement of quality of life and long-term survival.


Subject(s)
Cystic Fibrosis/surgery , Lung Transplantation/physiology , Adolescent , Adult , Child , Female , Follow-Up Studies , Forced Expiratory Volume , Graft Survival , Humans , Lung Transplantation/mortality , Male , Middle Aged , Patient Selection , Reoperation/statistics & numerical data , Retrospective Studies , Survival Analysis , Waiting Lists
17.
Clin Genet ; 72(1): 39-46, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17594398

ABSTRACT

The neonatal screening protocol for cystic fibrosis (CF) is based on a first determination of blood immunoreactive trypsin (IRT1), followed by a first level genetic test that includes the 31 worldwide most common mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (DNA31), and a second determination of blood immunoreactive trypsin (IRT2). This approach identifies, in addition to affected subjects, a high proportion of newborns with hypertrypsinaemia at birth, in whom only one mutation is identified and who have a negative or borderline sweat test and pancreatic sufficiency. Although it has been suggested that hypertrypsinaemia may be caused by a single CFTR mutation, whether such neonates should be merely considered as healthy carriers remains a matter of debate as hypertrypsinaemia at birth may be a biochemical marker of a CFTR malfunction because of a second mild mutation. We analyzed, by means of an extended sequencing protocol, 32 newborns who tested positive at an IRT1/DNA31/IRT2 screening protocol and in whom only one CFTR mutation was found. The results obtained demonstrate that 62.5% of these newborns were also carrying a second mild CFTR mutation. The high proportion of compound heterozygous subjects, combined with the results of a 4-year follow-up in nine of these subjects all of whom displaying initial CF clinical symptoms, suggest that it may be possible to use the IRT1/DNA31/IRT2 protocol of neonatal screening to identify newborns with atypical forms of CF. In view of these findings, an extended genetic search for subjects with compound heterozygosity and a periodic clinical assessment should be considered.


Subject(s)
Cystic Fibrosis/diagnosis , Cystic Fibrosis/genetics , Child, Preschool , Cystic Fibrosis/enzymology , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Follow-Up Studies , Genetic Testing , Genotype , Heterozygote , Humans , Infant , Infant, Newborn , Neonatal Screening , Trypsin/blood , Trypsinogen/blood
18.
Regul Pept ; 124(1-3): 187-93, 2005 Jan 15.
Article in English | MEDLINE | ID: mdl-15544858

ABSTRACT

AIM: To study adrenomedullin (AM) plasma levels in patients with severe lung disease and to analyze the relationship between AM and heart changes, hemodynamics and blood gases. METHODS: Case control study of 56 patients (36 men, 20 women) with severe lung disease and 9 control subjects (7 men, 2 women). Patients with end-stage pulmonary disease, including chronic obstructive pulmonary disease (COPD, n=11), cystic fibrosis (CF, 26), idiopatic pulmonary fibrosis (ILD, n=9), and idiopatic pulmonary arterial hypertension (PAH, n=10), who were evaluated for lung trasplantation between January 1997 and September 2000, and nine patients who underwent lung surgery for a solitary benign nodule. AM plasma levels in pulmonary artery (mixed venous blood, vein) and aorta or femoral artery (arterial, art), art and vein blood gases, pulmonary hemodynamics, systemic hemodynamics, two-dimensional transthoracic echocardiography and echo-Doppler study. RESULTS: Plasma AM (art and ven) levels were higher among patients' group compared to the controls (AMart p<0.02 and AMven p<0.04) for CF, ILD, PAH (AMart, pg ml(-1) Controls 13.7+/-3.6, COPD 22.8+/-6.2, CF 28.1+/-11.4, ILD 34.1+/-14.3, PAH 35.1+/-18.9; AMven, pg ml(-1) Controls 14.2+/-4.8, COPD 28.1+/-12.6, CF 31.7+/-14.1, ILD 38.7+/-16.5, PAH 40.1+/-4.4). We found with a trend towards higher concentration in ILD and PAH patients compared to COPD and CF but no statistical significant differences. Mixed-venous AM was higher than arterial AM in all groups resulting in AM uptake (AMPulmUp pg min(-1) Controls 4.8+/-22.6, COPD 21.1+/-44.9, CF 20.6+/-45.1, ILD 23.7+/-38.5, PAH 29.9+/-49.7). The univariate analysis showed a weak but significant correlation between AMart and mean systemic arterial pressure, heart rate, mean pulmonary arterial pressure and systemic vascular resistance. In the multivariate analysis, four variables emerged as independent factors of AMart including mean pulmonary arterial pressure, heart rate, mean systemic arterial pressure and left ventricular diastolic diameter (F=8.6, p<0.00001, r=0.60, r2=0.32). A similar weak correlation was apparent between AMven, systemic vascular resistance, and mean pulmonary arterial pressure. The results of multivariate analysis identify right atrial enlargement, mean right atrial pressure, heart rate and left ventricular dimensions as the only independent variables related to AMven (F=4.3, p<0.0004 r=0.56, r2=0.26). AM pulmonary uptake was significantly correlated with AMven (r=0.65), but not with hemodynamic, blood gas and echocardiographic variables. CONCLUSIONS: AM plasma levels are elevated in patients with severe lung disease in face of a preserved pulmonary uptake. These results suggest that the high AM plasma levels in patients with severe lung disease are not caused by a reduced pulmonary clearance, instead suggesting a systemic production.


Subject(s)
Lung Diseases/blood , Peptides/blood , Adrenomedullin , Adult , Cystic Fibrosis/blood , Cystic Fibrosis/metabolism , Cystic Fibrosis/physiopathology , Echocardiography , Female , Humans , Lung Diseases/metabolism , Lung Diseases/physiopathology , Male , Middle Aged , Peptides/metabolism , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/metabolism , Pulmonary Disease, Chronic Obstructive/physiopathology , Pulmonary Fibrosis/blood , Pulmonary Fibrosis/metabolism , Pulmonary Fibrosis/physiopathology
19.
Transpl Infect Dis ; 6(1): 41-5, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15225227

ABSTRACT

We report the case of a 24-year-old woman with cystic fibrosis in whom spondylodiscitis developed after bilateral sequential transplantation. The diagnostic work-up included magnetic resonance imaging, computed tomography-guided disk biopsy, histological examination, and cultures of disk specimens. The infective organism was D group Streptococcus and the patient was successfully treated with intravenous piperacillin followed by oral ampicillin. To our knowledge, this is the first reported case of spondylodiscitis after lung transplantation.


Subject(s)
Discitis/microbiology , Lung Transplantation/adverse effects , Streptococcal Infections/microbiology , Streptococcus/isolation & purification , Adult , Ampicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Cystic Fibrosis/microbiology , Discitis/drug therapy , Female , Humans , Piperacillin/therapeutic use , Streptococcal Infections/drug therapy , Treatment Outcome
20.
Eur Respir J ; 23(4): 569-74, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15083756

ABSTRACT

A simple exercise test would be useful for detecting exercise-induced asthma, a common problem in asthmatic children. The current study compared the 3-min step test with treadmill exercise for evaluating exercise-induced asthma in asthmatic children and assessed whether responses to both tests are influenced by baseline lung function and habitual physical activity. A series of 154 asthmatic children (84 male children; mean age 12.9 +/- 0.9 yrs) underwent a 3-min step-test and treadmill testing on different days within a week at least 24 h apart. Before both tests each subject did spirometry to obtain the baseline forced expiratory volume in one second (FEV1). After both exercise challenges all subjects did serial spirometry and the lowest FEV1 recorded over time was used to calculate the fall in FEV1 expressed as a percentage of the measured pre-exercise (baseline) value (% fall in FEV1) and the area above the FEV1 curve (AAC0-30 min) expressed as a percentage of the pre-exercise value. Changes in both exercise variables were also analysed in percentile subgroups defined by questionnaire answers on habitual physical activity in hours. The mean % fall in FEV1 was significantly higher for treadmill exercise than for the step test (15.0 +/- 7.5 versus 11.7 +/- 5.9); and the AAC0-30 min was larger for treadmill than for the step test (-261.6 +/- 139.9% versus -197.3 +/- 105.0% min). In all subgroups defined by habitual physical activity the mean % fall in FEV1 decreased more after treadmill exercise than after the step test. After step test and treadmill exercise no significant correlation was found between % fall in FEV1 and baseline lung function, or between % fall in FEV1 among groups defined by habitual physical activity. Although the 3-min step test yields a lower % fall in forced expiratory volume in one second (FEV1) and a lower value of the area above the FEV1 curve than treadmill testing, it is a quick, economical, reproducible and portable alternative procedure for identifying exercise-induced asthma in outpatients and epidemiological studies. Baseline lung function and habitual physical activity have no influence on the amount or duration of exercise-induced asthma.


Subject(s)
Asthma, Exercise-Induced/diagnosis , Exercise Test/classification , Adolescent , Analysis of Variance , Asthma, Exercise-Induced/physiopathology , Child , Female , Forced Expiratory Volume/physiology , Humans , Lung/physiopathology , Male , Motor Activity/physiology , Sensitivity and Specificity , Spirometry , Statistics, Nonparametric , Vital Capacity/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...